Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV

Vaccine

Volumn 29, Issue 38, 2011, Pages 6606-6613

  Liu, Ye V ^a   Massare, Michael J ^a   Barnard, Dale L ^b   Kort, Thomas ^a   Nathan, Margret ^a   Wang, Lei ^a   Smith, Gale ^a  

^a NOVAVAX INC   (United States)

^b UTAH STATE UNIVERSITY   (United States)

Author keywords

Baculovirus; Influenza; Lung virus titer; Neutralizing antibody; Severe acute respiratory syndrome; Virus like particles

Indexed keywords

ALUMINUM HYDROXIDE; CHIMERIC PROTEIN; IMMUNOLOGICAL ADJUVANT; INFLUENZA MATRIX 1 PROTEIN; INFLUENZA VIRUS HEMAGGLUTININ; MATRIX PROTEIN; NEUTRALIZING ANTIBODY; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS LIKE PARTICLE VACCINE; VIRUS SPIKE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; BACULOVIRUS EXPRESSION SYSTEM; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG SCREENING; FEMALE; IMMUNOGENICITY; INSECT CELL; LETHALITY; LUNG HOMOGENATE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PANDEMIC; PRIORITY JOURNAL; PROTEIN PURIFICATION; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; TREATMENT OUTCOME; VIRUS LIKE AGENT; VIRUS LOAD; VIRUS STRAIN; WEIGHT REDUCTION;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM HYDROXIDE; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BACULOVIRIDAE; BODY WEIGHT; DISEASE MODELS, ANIMAL; FEMALE; GENETIC VECTORS; INSECTS; LUNG; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; PROTEIN MULTIMERIZATION; RECOMBINANT PROTEINS; RODENT DISEASES; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; SURVIVAL ANALYSIS; VACCINES, VIROSOME; VIRAL ENVELOPE PROTEINS; VIRAL LOAD; VIRAL MATRIX PROTEINS; VIRAL VACCINES;

EID: 80051670910     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.06.111     Document Type: Article

References (53)

1. Enjuanes L., Dediego M.L., Alvarez E., Deming D., Sheahan T., Baric R. Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease. Virus Res 2008, 133(1):45-62.
2. World Health Organization. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. http://www.who.int/csr/sars/country/table2004_04_21/en/.
3. Ahmad A., Krumkamp R., Reintjes R. Controlling SARS: a review on China's response compared with other SARS-affected countries. Trop Med Int Health 2009, 14(Suppl. 1):36-45.
4. Beutels P., Jia N., Zhou Q.Y., Smith R., Cao W.C., de Vlas S.J. The economic impact of SARS in Beijing, China. Trop Med Int Health 2009, 14(Suppl. 1):85-91.
5. Chan-Yeung M., Ooi G.C., Hui D.S., Ho P.L., Tsang K.W. Severe acute respiratory syndrome. Int J Tuberc Lung Dis 2003, 7(12):1117-1130.
6. Drosten C., Günther S., Preiser W., van der Werf S., Brodt H.R., Becker S., et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003, 348(20):1967-1976.
7. Masters P.S. The molecular biology of coronaviruses. Adv Virus Res 2006, 66:193-292.
8. Li W., Moore M.J., Vasilieva N., Sui J., Wong S.K., Berne M.A., et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003, 426(6965):450-454.
9. Qiu M., Shi Y., Guo Z., Chen Z., He R., Chen R., et al. Antibody responses to individual proteins of SARS coronavirus and their neutralization activities. Microbes Infect 2005, 7(5-6):882-889.
10. Bisht H., Roberts A., Vogel L., Bukreyev A., Collins P.L., Murphy B.R., et al. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci USA 2004, 101(17):6641-6646.
11. Yang Z.Y., Kong W.P., Huang Y., Roberts A., Murphy B.R., Subbarao K., et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 2004, 428(6982):561-564.
12. Vogel L.N., Roberts A., Paddock C.D., Genrich G.L., Lamirande E.W., Kapadia S.U., et al. Utility of the aged BALB/c mouse model to demonstrate prevention and control strategies for severe acute respiratory syndrome coronavirus (SARS-CoV). Vaccine 2007, 25(12):2173-2179.
13. Bai B., Lu X., Meng J., Hu Q., Mao P., Lu B., et al. Vaccination of mice with recombinant baculovirus expressing spike or nucleocapsid protein of SARS-like coronavirus generates humoral and cellular immune responses. Mol Immunol 2007, 45:868-875.
14. Rihtaric D., Hostnik P., Steyer A., Grom J., Toplak I. Identification of SARS-like coronaviruses in horseshoe bats (Rhinolophus hipposideros) in Slovenia. Arch Virol 2010, 155(4):507-514.
15. Anderson L.J., Tong S. Update on SARS research and other possibly zoonotic coronaviruses. Int J Antimicrob Agents 2010, 36(November (Suppl. 1)):S21-S25. Epub 2010 (August 30).
16. Guan Y., Zheng B.J., He Y.Q., Liu X.L., Zhuang Z.X., Cheung C.L., et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 2003, 302(5643):276-278.
17. World Health Organization. China's latest SARS outbreak has been contained, but biosafety concerns remain-Update 7, 18 May 2004. http://www.who.int/csr/don/2004_05_18a/en/.
18. NIAID Category A, B, and C Priority Pathogens. http://www.niaid.nih.gov/topics/biodefenserelated/biodefense/research/pages/cata.aspx.
19. Spruth M., Kistner O., Savidis-Dacho H., Hitter E., Crowe B., Gerencer M., et al. A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses. Vaccine 2006, 24(5):652-661.
20. Marshall E., Enserink M. Medicine. Caution urged on SARS vaccines. Science 2004, 303(5660):944-946.
21. Qin E., Shi H., Tang L., Wang C., Chang G., Ding Z., et al. Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine. Vaccine 2006, 24(7):1028-1034.
22. Martin J.E., Louder M.K., Holman L.A., Gordon I.J., Enama M.E., Larkin B.D., et al. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a phase I clinical trial. Vaccine 2008, 26(50):6338-6343.
23. Bisht H., Roberts A., Vogel L., Subbarao K., Moss B. Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein. Virology 2005, 334(2):160-165.
24. Zhou Z., Post P., Chubet R., Holtz K., McPherson C., Petric M., et al. A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice. Vaccine 2006, 24(17):3624-3631.
25. Roy P., Noad R. Virus-like particles as a vaccine delivery system: myths and facts. Hum Vaccine 2008, 4(1):5-12.
26. Hsieh P.K., Chang S.C., Huang C.C., Lee T.T., Hsiao C.W., Kou Y.H., et al. Assembly of severe acute respiratory syndrome coronavirus RNA packaging signal into virus-like particles is nucleocapsid dependent. J Virol 2005, 79(22):13848-13855.
27. Huang Y., Yang Z.Y., Kong W.P., Nabel G.J. Generation of synthetic severe acute respiratory syndrome coronavirus pseudoparticles: implications for assembly and vaccine production. J Virol 2004, 78(22):12557-12565.
28. Mortola E., Roy P. Efficient assembly and release of SARS coronavirus-like particles by a heterologous expression system. FEBS Lett 2004, 576:174-178.
29. Ho Y., Lin P.H., Liu C.Y., Lee S.P., Chao Y.C. Assembly of human severe acute respiratory syndrome coronavirus-like particles. Biochem Biophys Res Commun 2004, 318(4):833-838.
30. Lu X., Chen Y., Bai B., Hu H., Tao L., Yang J. Immune responses against severe acute respiratory syndrome coronavirus induced by virus-like particles in mice. Immunology 2007, 122(4):496-502.
31. Bai B., Hu Q., Hu H., Zhou P., Shi Z., Meng J. Virus-like particles of SARS-like coronavirus formed by membrane proteins from different origins demonstrate stimulating activity in human dendritic cells. PLoS One 2008, 3(7):e2685.
32. Lokugamage K.G., Yoshikawa-Iwata N., Ito N., Watts D.M., Wyde P.R., Wang N., et al. Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV. Vaccine 2008, 26(6):797-808.
33. Roper R.L., Rehm K.E. SARS vaccines: where are we?. Expert Rev Vaccines 2009, 8(7):887-898.
34. Bright R.A., Carter D.M., Crevar C.J., Toapanta F.R., Steckbeck J.D., Cole K.S., et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One 2008, 3(1):e1501.
35. Song H., Wittman V., Byers A., Tapia T., Zhou B., Warren W., et al. In vitro stimulation of human influenza-specific CD8+ T cells by dendritic cells pulsed with an influenza virus-like particle (VLP) vaccine. Vaccine 2010, 28(34):5524-5532.
36. Almeida J., Tyrell D. The morphology of three previously uncharacterized human respiratory viruses that grow in organ culture. J Gen Virol 1967, 2:175-178.
37. Zhang Q.F., Cui J.M., Huang X.J., Lin W., Tan D.Y., Xu J.W., et al. Morphology and morphogenesis of severe acute respiratory syndrome (SARS)-associated virus. Acta Biochim Biophys Sin 2003, 35(6):587-591.
38. Drosten C., Lau A., Preiser W., So L., Yam L. SARS reference 2003, 41. Flying Publisher, http://www.sarsreference.com. 3rd ed. B.S. Kamps, C. Hoffmann (Eds.).
39. Bright R.A., Carter D.M., Daniluk S., Toapanta F.R., Ahmad A., Gavrilov V., et al. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 2007, 25(19):3871-3878.
40. Pushko P., Kort T., Nathan M., Pearce M.B., Smith G., Tumpey T.M. Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus. Vaccine 2010, 28(30):4771-4776.
41. Hall L.J., Clare S., Dougan G. Probing local innate immune responses after mucosal immunisation. J Immune Based Ther Vaccines 2010, 8(1):5.
42. Hamming I., Timens W., Bulthuis M.L., Lely A.T., Navis G.J., van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004, 203(2):631-637.
43. Ding Y., He L., Zhang Q., Huang Z., Che X., Hou J., et al. Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. J Pathol 2004, 203(2):622-630.
44. Chen J., Subbarao K. The immunobiology of SARS. Annu Rev Immunol 2007, 25:443-472.
45. Day C.W., Baric R., Cai S.X., Frieman M., Kumaki Y., Morrey J.D., et al. A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo. Virology 2009, 395(2):210-222.
46. Murti K.G., Portner A., Thoughton K., Deshpande K. Localization of proteins on viral nucleocapsids using immunoelectron microscopy. J Electron Microsc Tech 1985, 2:139-146.
47. Feng Q., Liu Y., Qu X., Deng H., Ding M., Lau T.L., et al. Baculovirus surface display of SARS coronavirus (SARS-CoV) spike protein and immunogenicity of the displayed protein in mice models. Immunology 2007, 122(4):496-502.
48. Lu B., Huang Y., Huang L., Li B., Zheng Z., Chen Z., et al. Effect of mucosal and systemic immunization with virus-like particles of severe acute respiratory syndrome coronavirus in mice. Immunology 2010, 130(2):254-261.
49. Ludwig C., Wagner R. Virus-like particles-universal molecular toolboxes. Curr Opin Biotechnol 2007, 18(6):537-545.
50. Grgacic E.V., Anderson D.A. Virus-like particles: passport to immune recognition. Methods 2006, 40(1):60-65.
51. López-Macías C, Ferat-Osorio E, Tenorio-Calvo A, Isibasi A, Talavera J, Arteaga-Ruiz O, et al. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico. Vaccine, under review.
52. Hu M.C., Jones T., Kenney R.T., Barnard D.L., Burt D.S., Lowell G.H. Intranasal protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice. Vaccine 2007, 25(34):6334-6340.
53. Ohkawa T., Volkman L.E., Welch M.D. Actin-based motility drives baculovirus transit to the nucleus and cell surface. J Cell Biol 2010, 190(2):187-195.